LexaGene Enters Collaboration to Incorporate Cancer Sequencing Technology into a New Product

BEVERLY, Mass., May 29, 2018 (GLOBE NEWSWIRE)  LexaGene Holdings Inc. (OTCQB:LXXGF) (TSX-V:LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, announced today that it has entered into an agreement with the Stanford University School of Medicine.  The agreement involves using a targeted sequencing technology developed in the laboratory of Dr. Hanlee Ji, a Stanford associate professor of medicine, in combination with LexaGene’s microfluidic instrument.  “LexaGene’s technology was originally designed for pathogen detection across very large markets – I’m The post LexaGene Enters Collaboration to Incorporate Cancer Sequencing Technology into a New Product appeared first on Public Wire.
http://bit.ly/2LF0dWo